GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.

Industry: Biological Products, (No Diagnostic Substances) Peers: Annexon Inc Arbutus Biopharma Corp Tango Therapeutics Inc Bioatla Inc CONCERT PHARMACEUTICALS, INC. Sutro Biopharma Inc Generation Bio Co. Immuneering Corp Omega Therapeutics, Inc.